(= 5-azacytidine; b-ribofuranosyl 5-azacytidine)
The ribonucleoside of 5-azacytosine.

Dictionary of molecular biology. 2004.

Look at other dictionaries:

  • azacytidine — noun A synthetic analogue of cytidine used in the treatment of myelodysplastic syndrome …   Wiktionary

  • 5-azacytidine — 5 azacytidine. См. 5 азацитидин. (Источник: «Англо русский толковый словарь генетических терминов». Арефьев В.А., Лисовенко Л.А., Москва: Изд во ВНИРО, 1995 г.) …   Молекулярная биология и генетика. Толковый словарь.

  • 5-azacytidine — 5 aza·cy·ti·dine fīv .az ə sit ə .dēn, sīt or azacytidine n an antineoplastic cytidine analog C8H12N4O5 that has been used experimentally in the treatment of some leukemias and cancers * * * 5 aza·cy·ti·dine (a″zə siґtĭ dēn)… …   Medical dictionary

  • Azacitidine — Systematic (IUPAC) name 4 amino 1 β D ribofuranosyl 1,3,5 triazin 2(1H) one Clinical data Trade names …   Wikipedia

  • AZI1 — 5 azacytidine induced 1 Identifiers Symbols AZI1; AZ1; Cep131; ZA1 External IDs OM …   Wikipedia

  • AZI2 — 5 azacytidine induced 2, also known as AZI2, is a human gene.cite web | title = Entrez Gene: AZI2 5 azacytidine induced 2| url = Cmd=ShowDetailView TermToSearch=64343| accessdate = ] PBB Summary… …   Wikipedia

  • Myelodysplastic syndrome — Classification and external resources ICD 10 D46 ICD 9 238.7 …   Wikipedia

  • Азацитидин — Химическое соединение …   Википедия

  • Fragile sites — There are two kinds of fragile sites: common and rare fragile sites. Rare fragile sites are found in less than 5% of the population and are composed of tri or dinucleotide repeats that may cause spontaneous breaks during replication, frequently… …   Wikipedia

  • František Šorm — (February 28 1913 in Prague November 18 1980) was a Czech chemist known for synthesis of natural compounds, mainly terpenes and biologically active components of plants. Šorm was the founder of the [ en.html… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.